Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending in the fourth quarter of fiscal 2024 as trials for its treatment ...

HC Wainwright reissued their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has ...

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall ...

European equities traded in the US as American depositary receipts kicked off the week on strong note late Monday morning, surging 1.83% higher to 1,442.61 on the S&P Europe Select ADR Index. From ...

The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it ...

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization ---- Adds novel, high-capacity, local-delivery platform ...

Less than 20 years after the first biopharmaceutical, insulin, was approved, a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline.

New York State Common Retirement Fund boosted its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 13.5% in the fourth quarter, Holdings Channel reports. The fund owned ...

LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line ...

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an ...

The company reported a Q4 EPS of $0.15, which was $0.07 higher than the analyst estimate of $0.08. Revenue for the quarter came in at $108.19 million, outpacing the consensus estimate of $97.66 ...